We evaluated how the impact of apolipoprotein E4 (APOE4) differs according to age in Alzheimer’s disease (AD) patients. We recruited 846 AD patients and 815 cognitively normal controls and categorized into three groups with respect to their age (<65, 65–74, and ≥75 years). We evaluated the risk of AD in APOE4 carriers and compared cortical thickness and cognitive function according to APOE4 status in each age group. At the point of this study, in young (<65 years) AD, APOE4 noncarriers had the most severe frontal and perisylvian atrophy, while in old (≥75 years) AD, APOE4 carriers had the most severe medial temporal atrophy. In AD under 75 years, APOE4 noncarriers and heterozygotes showed worse performance in language, visuospatial, and frontal function compared to homozygotes, while, in old (≥75 years) AD, APOE4 homozygotes showed worse performance in memory compared to noncarriers. As the detrimental effects of APOE4 seen in older AD patients were not found in younger AD patients, we suggest that some unrevealed factors are associated with cortical atrophy and non-amnestic cognitive dysfunction in young AD with APOE4 noncarriers.
Chartier-HarlinMC, ParfittM, LegrainS, Perez-TurJ, BrousseauT, EvansA, BerrC, VidalO, RoquesP, GourletV, et al. (1994) Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer’s disease: Analysis of the 19q13.2 chromosomal region. Hum Mol Genet3, 569–574.
2.
CaselliRJ, DueckAC, OsborneD, SabbaghMN, ConnorDJ, AhernGL, BaxterLC, RapcsakSZ, ShiJ, WoodruffBK, LockeDE, SnyderCH, AlexanderGE, RademakersR, ReimanEM (2009) Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med361, 255–263.
3.
CaselliRJ, DueckAC, LockeDEC, Hoffman-SnyderCR, WoodruffBK, RapcsakSZ, ReimanEM (2011) Longitudinal modeling of frontal cognition in APOE epsilon 4 homozygotes, heterozygotes, and noncarriers. Neurology76, 1383–1388.
4.
KimYJ, ChoH, KimYJ, KiCS, ChungSJ, YeBS, KimHJ, KimJH, KimST, LeeKH, JeonS, LeeJM, ChinJ, KimJH, NaDL, SeongJK, SeoSW (2015) Apolipoprotein e4 affects topographical changes in hippocampal and cortical atrophy in Alzheimer’s disease dementia: A five-year longitudinal study. J Alzheimers Dis44, 1075–1085.
BlackerD, HainesJL, RodesL, TerwedowH, GoRC, HarrellLE, PerryRT, BassettSS, ChaseG, MeyersD, AlbertMS, TanziR (1997) ApoE-4 and age at onset of Alzheimer’s disease: The NIMH genetics initiative. Neurology48, 139–147.
9.
FarrerLA, CupplesLA, HainesJL, HymanB, KukullWA, MayeuxR, MyersRH, Pericak-VanceMA, RischN, van DuijnCM (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA278, 1349–1356.
10.
CorderEH, SaundersAM, StrittmatterWJ, SchmechelDE, GaskellPC, SmallGW, RosesAD, HainesJL, Pericak-VanceMA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science261, 921–923.
11.
MigliaccioR, AgostaF, PossinKL, CanuE, FilippiM, RabinoviciGD, RosenHJ, MillerBL, Gorno-TempiniML (2015) Mapping the progression of atrophy in early- and late-onset Alzheimer’s disease. J Alzheimers Dis46, 351–364.
12.
NohY, JeonS, LeeJM, SeoSW, KimGH, ChoH, YeBS, YoonCW, KimHJ, ChinJ, ParkKH, HeilmanKM, NaDL (2014) Anatomical heterogeneity of Alzheimer disease: Based on cortical thickness on MRIs. Neurology83, 1936–1944.
13.
MendezMF, LeeAS, JoshiA, ShapiraJS (2012) Nonamnestic presentations of early-onset Alzheimer’s disease. Am J Alzheimers Dis Other Demen27, 413–420.
14.
FilleyCM, KellyJ, HeatonRK (1986) Neuropsychologic features of early- and late-onset Alzheimer’s disease. Arch Neurol43, 574–576.
15.
GaltonCJ, PattersonK, XuerebJH, HodgesJR (2000) Atypical and typical presentations of Alzheimer’s disease: A clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain3, 484–498.
16.
van der FlierWM, PijnenburgYA, FoxNC, ScheltensP (2011) Early-onset versus late-onset Alzheimer’s disease: The case of the missing APOE varepsilon4 allele. Lancet Neurol10, 280–288.
17.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
McKeithIG, GalaskoD, KosakaK, PerryEK, DicksonDW, HansenLA, SalmonDP, LoweJ, MirraSS, ByrneEJ, LennoxG, QuinnNP, EdwardsonJA, IncePG, BergeronC, BurnsA, MillerBL, LovestoneS, CollertonD, JansenEN, BallardC, de VosRA, WilcockGK, JellingerKA, PerryRH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology47, 1113–1124.
20.
ParkKW, KimHS, CheonSM, ChaJK, KimSH, KimJW (2011) Dementia with Lewy bodies versus Alzheimer’s disease and Parkinson’s disease dementia: A comparison of cognitive profiles. J Clin Neurol7, 19–24.
21.
KuHM, KimJH, KwonEJ, KimSH, LeeHS, KoJH, AnSM, KimDG (2004) A study on the reliability and validity of Seoul-Instrumental Activities of Daily Living (S-IADL). J Korean Neuropsychiatr Assoc2, 189–199.
22.
RossorMN, FoxNC, MummeryCJ, SchottJM, WarrenJD (2010) The diagnosis of young-onset dementia. Lancet Neurol9, 793–806.
23.
MendezMF (2006) The accurate diagnosis of early-onset dementia. Int J Psychiatry Med36, 401–412.
24.
HarveyRJ, Skelton-RobinsonM, RossorMN (2003) The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry74, 1206–1209.
25.
CollinsDL, NeelinP, PetersTM, EvansAC (1994) Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr18, 192–205.
26.
SledJG, ZijdenbosAP, EvansAC (1998) A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging17, 87–97.
27.
ZijdenbosA, EvansA, RiahiF, SledJ, ChuiJ, KollokianV (1996) Automatic quantification of multiple sclerosis lesion volume using stereotaxic space. Vis Biomed Comput1131, 439–448.
28.
KimJS, SinghV, LeeJK, LerchJ, Ad-Dab’baghY, MacDonaldD, LeeJM, KimSI, EvansAC (2005) Automated 3-D extraction and evaluation of the inner and outer cortical surfaces using a Laplacian map and partial volume effect classification. Neuroimage27, 210–221.
29.
ImK, LeeJM, LeeJ, ShinYW, KimIY, KwonJS, KimSI (2006) Gender difference analysis of cortical thickness in healthy young adults with surface-based methods. Neuroimage31, 31–38.
AhnHJ, ChinJ, ParkA, LeeBH, SuhMK, SeoSW, NaDL (2010) Seoul Neuropsychological Screening Battery-dementia version (SNSB-D): A useful tool for assessing and monitoring cognitive impairments in dementia patients. J Korean Med Sci25, 1071–1076.
32.
KangY (2006) A normative Study of the Korean-Mini Mental State Examination (K-MMSE) in the Elderly. Korean J Psychol25, 1–12.
33.
LiuCC, KanekiyoT, XuH, BuG (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol9, 106–118.
34.
TostoG, ReitzC (2013) Genome-wide association studies in Alzheimer’s disease: A review. Curr Neurol Neurosci Rep13, 381.
35.
LanoiseleeHM, NicolasG, WallonD, Rovelet-LecruxA, LacourM, RousseauS, RichardAC, PasquierF, Rollin-SillaireA, MartinaudO, Quillard-MuraineM, de la SayetteV, Boutoleau-BretonniereC, Etcharry-BouyxF, ChauvireV, SarazinM, le BerI, EpelbaumS, JonveauxT, RouaudO, CeccaldiM, FelicianO, GodefroyO, FormaglioM, CroisileB, AuriacombeS, ChamardL, VincentJL, SauveeM, Marelli-TosiC, GabelleA, OzsancakC, ParienteJ, PaquetC, HannequinD, CampionD, collaborators of the CNRMAJp (2017) APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. PLoS Med14, e1002270.
36.
NicolasG, CharbonnierC, CampionD (2016) From common to rare variants: The genetic component of Alzheimer disease. Hum Hered81, 129–141.
37.
NicolasG, WallonD, CharbonnierC, QuenezO, RousseauS, RichardAC, Rovelet-LecruxA, CoutantS, Le GuennecK, BacqD, GarnierJG, OlasoR, BolandA, MeyerV, DeleuzeJF, MunterHM (2016) Screening of dementia genes by whole-exome sequencing in early-onset Alzheimer disease: Input and lessons. Eur J Hum Genet24, 710–716.
38.
ChuangYF, HaydenKM, NortonMC, TschanzJ, BreitnerJC, Welsh-BohmerKA, ZandiPP (2010) Association between APOE epsilon4 allele and vascular dementia: The Cache County study. Dement Geriatr Cogn Disord29, 248–253.
39.
ManningEN, BarnesJ, CashDM, BartlettJW, LeungKK, OurselinS, FoxNC (2014) APOE epsilon4 is associated with disproportionate progressive hippocampal atrophy in AD. PLoS One9, e97608.
40.
RaberJ, HuangY, AshfordJW (2004) ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging25, 641–650.
41.
ChanES, ShettyMS, SajikumarS, ChenC, SoongTW, WongBS (2016) ApoE4 expression accelerates hippocampus-dependent cognitive deficits by enhancing Abeta impairment of insulin signaling in an Alzheimer’s disease mouse model. Sci Rep6, 26119.
42.
HansenLA, DeTeresaR, DaviesP, TerryRD (1988) Neocortical morphometry, lesion counts, and choline acetyltransferase levels in the age spectrum of Alzheimer’s disease. Neurology38, 48–54.
43.
HoGJ, HansenLA, AlfordMF, FosterK, SalmonDP, GalaskoD, ThalLJ, MasliahE (2002) Age at onset is associated with disease severity in Lewy body variant and Alzheimer’s disease. Neuroreport13, 1825–1828.
44.
ChoH, ChoiJY, LeeSH, LeeJH, ChoiYC, RyuYH, LeeMS, LyooCH (2017) Excessive tau accumulation in the parieto-occipital cortex characterizes early-onset Alzheimer’s disease. Neurobiol Aging53, 103–111.
